Fangzhou Launches Partnership for "AI + Hepatitis Prevention & Control Training Center" at the Greater Bay Area International Liver Disease Forum

April 16, 2025 06:30 PM PDT | By Cision

Fangzhou Launches Partnership for — Image source: Kalkine Media

Recent News

Hitpaw Online Launches Its Ai Video Generator For Effortless Creation

Gutscheine7.De Becomes A Go To Savings Platform For U.s. Tourists Visi...

PepeX vs Dogecoin: Why PepeX is a better investment in 2025

Long DASH/USD: oversold recovery triggers bullish setup as RSI crosses...

GUANGZHOU, China, April 17, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven healthcare solutions, partnered with the Guangdong Provincial Liver Disease Institute at the 2025 Greater Bay Area International Liver Disease Forum to launch the "AI + Hepatitis Prevention and Control Training Center". This collaboration highlights the Company's pioneering efforts in leveraging artificial intelligence for advanced liver disease management.

Dr. Xie Fangmin, founder, chairman, and CEO of Fangzhou, commented, "Our role in establishing this training center highlights the Company's technological excellence and commitment to social responsibility. By integrating our AI innovations with the Institute's clinical expertise, we aim to improve access to high-quality hepatology care. Fangzhou will focus on smart screening tools and AI-assisted treatment protocols to set new standards in liver disease prevention and management."

Advancing AI-Assisted Liver Care and Patient Well-Being
The creation of the Training Center recognizes the Company's achievements in "AI-enabled full-cycle liver disease management", and also reflects the Company's expected role in continuing to apply cutting-edge AI technologies to advance liver disease prevention and treatment. As we work toward the goal of eliminating hepatitis as a major public health concern by 2030, the Company remains committed to its approach centered on patient well-being. Moving forward, the Company will continue to leverage AI as a core driver of innovation in the prevention and management of liver disease, while further enhancing standards for comprehensive full-cycle care. By deepening collaboration with research institutions, we aim to accelerate Guangdong's efforts to mitigate the impact of viral hepatitis on public health.

About Fangzhou Inc.

Fangzhou Inc. (06086.HK) is China's leading online chronic disease management platform, serving 49.2 million registered users and 223,000 physicians (as of December 31, 2024). The Company specializes in delivering tailored medical care and precision medicine solutions. For more information, visit https://investors.jianke.com.

About the "2025 Greater Bay Area International Forum on Liver Diseases"

The forum gathered distinguished representatives from government, industry, academia, research, and medical sectors to address cutting-edge developments in hepatology. Through expert presentations and in-depth discussions, it established a robust academic exchange platform for eliminating viral hepatitis and advancing liver disease diagnosis and treatment, thereby fostering synergistic growth between clinical practice and scientific research.

Media Contact

For further inquiries or interviews, please reach out to:
Xingwei Zhao Associate Director of Public Relations Email: [email protected]

Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.